Publicaciones en colaboración con investigadores/as de Charité (30)

2024

  1. A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function

    European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 707-729

  2. An atlas of cells in the human tonsil

    Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. DNA methylation as the link between migration and the major noncommunicable diseases: The RODAM study

    Epigenomics, Vol. 13, Núm. 9, pp. 653-666

2020

  1. H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts

    Clinical Epigenetics, Vol. 12, Núm. 1

  2. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767

  3. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2018

  1. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

    European Journal of Heart Failure, Vol. 20, Núm. 9, pp. 1290-1299

  2. Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis

    FASEB Journal, Vol. 32, Núm. 11, pp. 6066-6078

  3. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial)

    European Journal of Heart Failure, Vol. 20, Núm. 3, pp. 460-470

  4. Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis

    Cancer Cell, Vol. 33, Núm. 3, pp. 417-434.e7

2017

  1. Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction

    Cardiovascular Research, Vol. 113, Núm. 8, pp. 906-914

2016

  1. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome

    Annals of Oncology, Vol. 27, Núm. 9, pp. 1788-1793

  2. Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense

    Nature Immunology, Vol. 17, Núm. 9, pp. 1037-1045

  3. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

    Nature Communications, Vol. 7

2015

  1. Strong induction of iodothyronine deiodinases by chemotherapeutic selenocompounds

    Metallomics, Vol. 7, Núm. 2, pp. 347-354

2013

  1. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model

    Circulation: Heart Failure, Vol. 6, Núm. 6, pp. 1239-1249